Trial Profile
A Prospective, Multi Centre, Observational, Data Collection Registry Study To Monitor The Routine Clinical Use Of Mabtas (Rituximab 100 Mg / 500 Mg Concentrate For Solution For Infusion, Manufactured By Intas Pharmaceuticals Ltd) In Indian Patients. - Mabtas registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 28 Sep 2016 New trial record